0000885725false00008857252026-11-192026-11-190000885725us-gaap:CommonStockMember2026-11-192026-11-190000885725bsx:SeniorNotedue2027Member2026-11-192026-11-19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
_____________________________________________________________________
Date of Report (Date of earliest event reported): November 19, 2026
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
| | | | | | | | | | | | | | | | | | | | |
| Delaware | | 1-11083 | | 04-2695240 |
| (State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
300 Boston Scientific Way, Marlborough, Massachusetts 01752-1234
(Address of principal executive offices) (Zip Code)
(508) 683-4000
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | | | | | |
| ☐ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
| Title of each class | | Trading Symbol | | Name of each exchange on which registered |
| Common Stock, $0.01 par value per share | | BSX | | New York Stock Exchange |
| 0.625% Senior Notes due 2027 | | BSX27 | | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On November 19, 2026, Boston Scientific Corporation (the “Company”) entered into an Underwriting Agreement (as supplemented by the Terms Agreement, also dated November 19, 2026, the “USD Underwriting Agreement”), among the Company and the representatives of the several underwriters named in the USD Underwriting Agreement (the “USD Underwriters”), in connection with the pricing of $3,000,000,000 aggregate principal amount of the Company’s U.S. dollar-denominated senior notes (the “USD Offering”). Pursuant to the USD Underwriting Agreement, the USD Underwriters agreed to purchase $1,000,000,000 in aggregate principal amount of 5.375% Senior Notes due 2029, $750,000,000 in aggregate principal amount of 5.500% Senior Notes due 2031, $750,000,000 in aggregate principal amount of 5.750% Senior Notes due 2033 and $500,000,000 in aggregate principal amount of 5.875% Senior Notes due 2036 (collectively, the “USD Notes”).
In addition, on November 19, 2026, the Company, as guarantor, and American Medical Systems Europe B.V. (“AMS Europe”), its indirect wholly owned finance subsidiary, as issuer, entered into an Underwriting Agreement (as supplemented by the Terms Agreement, also dated November 19, 2026, the “Euro Underwriting Agreement” and, together with the USD Underwriting Agreement, the “Underwriting Agreements”), among the Company, AMS Europe and the several underwriters named in the Euro Underwriting Agreement (the “Euro Underwriters” and, together with the USD Underwriters, the “Underwriters”), in connection with the pricing of €4,250,000,000 aggregate principal amount of AMS Europe’s euro-denominated senior notes (the “Euro Offering” and, together with the USD Offering, the “Offerings”). Pursuant to the Euro Underwriting Agreement, the Euro Underwriters agreed to purchase €500,000,000 in aggregate principal amount of Floating Rate Notes due 2028 (the "Floating Rate Notes"), €500,000,000 aggregate principal amount of 3.875% Senior Notes due 2028, €750,000,000 in aggregate principal amount of 4.125% Senior Notes due 2030, €750,000,000 in aggregate principal amount of 4.500% Senior Notes due 2034, €1,000,000,000 in aggregate principal amount of 4.750% Senior Notes due 2038 and €750,000,000 aggregate principal amount of 5.125% Senior Notes due 2046 (collectively, with the Floating Rate Notes, the “Euro Notes” and, together with the USD Notes, the “Notes”). The Euro Notes will be fully and unconditionally guaranteed by the Company.
The Offerings are expected to close on December 1, 2026. The Notes are being offered pursuant to the shelf registration statement on Form S-3 of the Company and AMS Europe (File No. 333-285032). The Underwriting Agreements contain customary representations, warranties and agreements of the Company and, in the case of the Euro Underwriting Agreement, AMS Europe, and customary conditions to closing, indemnification rights and obligations of the parties and termination provisions. The Underwriters and their affiliates have performed commercial banking, investment banking and advisory services for the Company from time to time for which they have received customary fees and expenses. The Underwriters and their affiliates may, from time to time, engage in transactions with and perform services for the Company and AMS Europe in the ordinary course of their business.
The Company intends to use the net proceeds from the Offerings, together with short-term borrowings and/or borrowings under its credit agreement(s) and cash on hand, to finance the cash consideration payable in connection with the Company’s previously announced acquisition of Penumbra, Inc. (“Penumbra”) and to pay related fees and expenses and, to the extent that the net proceeds from the Offerings are not used for such purposes, for general corporate purposes, which may include, among other things, short term investments, reduction of short term debt, funding of working capital and potential future acquisitions.
On January 14, 2026, the Company entered into an agreement and plan of merger (as such agreement may be amended, modified or supplemented, or any provision thereof waived, the “Merger Agreement”) to acquire Penumbra for a combination of cash and shares of common stock of the Company (the “Penumbra Acquisition”). The Offerings are not conditioned upon the completion of the Penumbra Acquisition, which, if completed, will occur subsequent to the closing of the Offerings. However, if (i) the Penumbra Acquisition is not completed on or before the later of (x) January 14, 2027 (as such date may be extended in accordance with the Merger Agreement to no later than January 14, 2028) and (y) if applicable, the date that is five business days after any later date to which the Company and Penumbra may agree to extend the “Outside Date” in the Merger Agreement as notified to the trustee under the indenture and, if applicable, the paying agent or (ii) the Company and AMS Europe notify the trustee under the indenture and, if applicable, the paying agent that the Company will not pursue completion of the Penumbra Acquisition, the Company and AMS Europe will be required to redeem each series of the USD Notes and the Euro Notes (other than the Floating Rate Notes), respectively, at a special mandatory redemption price equal to 101% of the aggregate principal amount of such series of Notes, plus accrued and unpaid interest, if any, to, but excluding, the special mandatory redemption date (as described in the Notes).
The foregoing descriptions of the USD Underwriting Agreement and the Euro Underwriting Agreement are summaries and are qualified in their entirety by reference to such documents, which are attached as Exhibits 1.1 and 1.2 to this Current Report on Form 8-K, respectively, and both of which are incorporated herein by reference.
Item 2.03 Creation of a Direct Financial Obligation of a Registrant.
The information set forth under Item 1.01 is incorporated herein by reference.
Item 8.01 Other Events.
On November 19, 2026, the Company issued a press release pertaining to the events described in this Current Report on Form 8-K, a copy of which is attached as Exhibit 99.1 hereto and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| | | | | | | | |
| Exhibit No. | | Description |
| 1.1 | | |
| 1.2 | | |
| 99.1 | | |
| 104 | | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | | | | |
| Date: | November 20, 2026 | BOSTON SCIENTIFIC CORPORATION |
| | | |
| | By: | /s/ Susan Thompson |
| | | Susan Thompson |
| | | Vice President, Chief Corporate Counsel and Assistant Secretary |